A partnership between JDRF and Janssen Pharmaceuticals seeks ways to intercept the disease before it progresses.
Sejal Saraiya, PharmD
Advertisement
Articles by Sejal Saraiya, PharmD
Advertisement
Latest Updated Articles
- Are Low-Cal Sweeteners at the End of Their Game?
December 4th 2014
- The Use and Implementation of Standardized Treatment Pathways
February 16th 2015
- Innovation and the Role of Alternative Markers of Efficacy
February 16th 2015
- Is It Possible to Prevent or Delay Type 1 Diabetes?
November 15th 2015
- Origins and Evidence Behind New ADA Recommendations for Pediatric A1C
September 19th 2014
- Thyroid Cancer: Increased Incidence or Improved Diagnosis?
September 19th 2014
Advertisement
Advertisement
Trending on AJMC
1
Flatiron’s AI-Driven Telescope Makes Data Access More User-Friendly
2
First Generic of Priftin Approved by FDA for Tuberculosis Treatment and Prevention
3
Mixed Phase 3 Results for IB6-Targeting ADC Raise Questions on Optimal Use in NSCLC
4
Social Factors May Match, Outpace Genetic Risk in Disease Prediction
5